Trusted by developers of HS therapies
Our technology empowers patient communities and has proven success with hidradenitis suppurative patients. As a technology platform, it generates the patient-reported, longitudinal data EHRs, claims, and trials miss. You license exactly the insight you need; we hold the governance, so your team holds nothing.
EHRs, claims, and clinical trials share one blind spot. They capture the visit, the bill, and the clinician's interpretation — and almost nothing in between.
As therapies get more targeted and competitive, that gap drives the questions you can't answer for payers, providers, and regulators.
This isn't an analytics problem. The data doesn't need to be cleaned — it needs to be generated.
Turnaround · days
Mine 2+ years of existing journal data. Treatment histories, pain trajectories, flare patterns — available now, no new enrollment.
Turnaround · weeks
Deploy custom instruments to thousands of research-consented patients. PROs, treatment satisfaction, switching behavior — delivered in weeks.
Turnaround · quarters
A dedicated cohort with weekly journaling and monthly QoL surveys. The premium play for long-term, patient-reported RWE.
| Research type | Traditional CRO | Jenevive Health |
|---|---|---|
| Retrospective analysis | 3–6 months | Days — already in the Vault |
| Survey study | 6–12 months | Weeks — deploy to consented users |
| Longitudinal outcomes | 12–24 months | Quarters — cohort activated immediately |
Direct-from-patient data is operationally and legally heavy. We carry that weight so you don't have to.
We own consent and re-consent, privacy, auditability, provenance, and longitudinal patient operations. You license access to the answers — not a dataset you'd have to store, secure, and defend.
Because the community already exists and is consented, studies start without site activation, physician recruitment, or investigator agreements — the slowest, most expensive parts of traditional research.
Because the app is part of patients' daily lives, they record flares, side effects, and treatment switches as they occur — not whenever the next appointment and records pipeline catches up. Sustained, high-frequency data a one-time registry can't match.
Engage at any depth — a single report, a quarterly subscription, or a dedicated cohort — and structure rights to match, from shared insights to time-bound exclusive access where it matters to you.
A deeply engaged HS community today — running on a platform built to extend to the next chronic, symptom-driven condition.
Cross-sectional survey covering comorbidities, treatment experience, and patient perceptions.
Dataset availableQualitative and longitudinal insight into real-world treatment perceptions.
Report availableLongitudinal study tracking real-world performance and drug survival via weekly journaling and monthly QoL surveys.
Launching in 2026
Patient-direct, between-visit, decision-grade — without building or governing the infrastructure yourself.